Lansoprazolo Eg

Lansoprazole, the active ingredient in Lansoprazolo Eg, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is employed in the management of acid‑related gastrointestinal conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and Helicobacter pylori eradication regimens. GNH USA supplies Lansoprazolo Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazolo Eg, a proton pump inhibitor, is used to treat disorders characterised by excess gastric acid. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and regurgitation by lowering acid exposure. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence through acid suppression. - Erosive esophagitis: heals inflamed esophageal lining by reducing gastric acid contact. - Helicobacter pylori eradication (in combination): enhances antibiotic effectiveness by creating a less acidic gastric environment.

Adverse reactions may occur with lansoprazole therapy.

Common Side Effects: - Headache: mild to moderate pain often resolves without intervention. - Diarrhoea: loose stools that may be transient. - Nausea: feeling of unease or upset stomach. - Abdominal pain: discomfort in the stomach region.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing requiring immediate medical attention. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat, seizures if untreated. - Clostridioides difficile‑associated diarrhoea: severe watery stools, fever, abdominal cramping, may need hospitalisation.

Before initiating therapy, consider the following precautions. - Assess renal function: adjust use in patients with severe impairment. - Monitor electrolytes: especially magnesium and potassium during prolonged treatment. - Avoid use in individuals with known hypersensitivity to lansoprazole or other PPIs. - Use with caution in elderly patients: increased risk of bone fractures and infections. - Review concomitant medications: potential for drug‑drug interactions. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Lansoprazole may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased absorption, leading to sub‑therapeutic antiviral levels.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, require more frequent coagulation testing. - Methotrexate: elevated serum concentrations, monitor for toxicity. - Digoxin: increased levels, observe for signs of digoxin toxicity.